David Kerr
Overview
Explore the profile of David Kerr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
289
Citations
10140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tian T, Ho C, Ayers A, Aaron R, Klonoff D, Ahn D, et al.
Diabetes Care
. 2025 Mar;
PMID: 40072890
Objective: Diabetes devices, including continuous glucose monitors (CGMs) and insulin pumps, may significantly affect environmental sustainability and long-term resilience. Research Design And Methods: This observational study enrolled 49 adults with...
2.
Shah V, Kerr D
Lancet Diabetes Endocrinol
. 2025 Feb;
13(3):172-174.
PMID: 39923788
No abstract available.
3.
Wang Z, Xia B, Qi S, Zhang X, Zhang X, Li Y, et al.
Elife
. 2024 Dec;
12.
PMID: 39699952
Bestrophin isoform 4 () is a newly identified subtype of the calcium-activated chloride channel family. Analysis of colonic epithelial cell diversity by single-cell RNA-sequencing has revealed the existence of a...
4.
Rhee C, Gianchandani R, Kerr D, Philis-Tsimikas A, Kovesdy C, Stanton R, et al.
J Diabetes Sci Technol
. 2024 Nov;
19(1):217-245.
PMID: 39611379
This report represents the conclusions of 15 experts in nephrology and endocrinology, based on their knowledge of key studies and evidence in the field, on the role of continuous glucose...
5.
Ayers A, Ho C, Kerr D, Cichosz S, Mathioudakis N, Wang M, et al.
J Diabetes Sci Technol
. 2024 Nov;
19(1):246-264.
PMID: 39578435
Artificial intelligence (AI) is increasingly being used to diagnose complications of diabetes. Artificial intelligence is technology that enables computers and machines to simulate human intelligence and solve complicated problems. In...
6.
Tu Y, Wu H, Zhong C, Liu Y, Xiong Z, Chen S, et al.
Gut
. 2024 Nov;
74(4):613-627.
PMID: 39486886
Background: Genomic screening uncovered interferon-gamma (IFNγ) pathway defects in tumours refractory to immune checkpoint blockade (ICB). However, its non-mutational regulation and reversibility for therapeutic development remain less understood. Objective: We...
7.
Ayers A, Ho C, Wong J, Kerr D, Mader J, Klonoff D
J Diabetes Sci Technol
. 2024 Oct;
:19322968241288923.
PMID: 39394887
No abstract available.
8.
Klonoff D, Freckmann G, Pleus S, Kovatchev B, Kerr D, Tse C, et al.
J Diabetes Sci Technol
. 2024 Oct;
18(6):1346-1361.
PMID: 39369312
Introduction: An error grid compares measured versus reference glucose concentrations to assign clinical risk values to observed errors. Widely used error grids for blood glucose monitors (BGMs) have limited value...
9.
Sato Imuro S, Sabharwal A, Bevier W, Kerr D
Sci Rep
. 2024 Sep;
14(1):22098.
PMID: 39333162
The discrepancy between estimated glycemia from HbA values and actual average glucose (AG) levels has significant implications for treatment decisions and patient understanding. Factors contributing to the gap include red...
10.
Pai R, Barua S, Kim B, McDonald M, Wierzchowska-McNew R, Pai A, et al.
J Diabetes Sci Technol
. 2024 Sep;
:19322968241274800.
PMID: 39311452
Background: Continuous glucose monitoring (CGM) systems allow detailed assessment of postprandial glucose responses (PPGR), offering new insights into food choices' impact on dysglycemia. However, current approaches to analyze PPGR using...